GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Certara Inc (MEX:CERT) » Definitions » Float Percentage Of Total Shares Outstanding

Certara (MEX:CERT) Float Percentage Of Total Shares Outstanding : 75.19% (As of Jun. 11, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Certara Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Certara's float shares is 120.94 Mil. Certara's total shares outstanding is 160.84 Mil. Certara's float percentage of total shares outstanding is 75.19%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Certara's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Certara's Institutional Ownership is 56.10%.


Certara Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Certara's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=120.94/160.84
=75.19%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Certara (MEX:CERT) Business Description

Industry
Traded in Other Exchanges
Address
100 Overlook Center, Suite 101, Princeton, NJ, USA, 08540
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The group has a business presence in the United States, EMEA, and other regions, of which a majority of revenue is derived from the United States.